ARCHIMEDES ANNOUNCES BIOSIMILARS FIRST™, AN INDUSTRY LEADING PROGRAM TO DRIVE BIOSIMILAR ADOPTION IN 2024

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

BRENTWOOD, Tenn., Jan. 11, 2024 /PRNewswire/ -- Archimedes, a recognized leader in specialty drug management solutions, announced BiosimilarsFirst™, a program, which excludes Humira from formulary in favor of low cost, low WAC biosimilars.

Metadata

Provider:

PR Newswire

Retrieved on:

Thursday, January 11, 2024

Information

Tags:

WAC, PBM, Patient, Publishing, Social media, Pharmacy, FDA, Physician, Generic drug

Geotags:

TENNESSEE

Organisation:

ARCHIMEDES

Summary

Key Points:

BRENTWOOD, Tenn., Jan. 11, 2024 /PRNewswire/ -- Archimedes, a recognized leader in specialty drug management solutions, announced BiosimilarsFirst™, a program, which excludes Humira from formulary in favor of low cost, low WAC biosimilars.
BiosimilarsFirst is projected to drive industry-leading adoption of biosimilars for autoimmune diseases, providing plan sponsor savings of 65% plus and more affordable treatment options for patients.
Archimedes' BiosimilarsFirst program stands in direct contrast to the PBM market's approach by preferring low cost biosimilars and excluding both brand and high cost biosimilars.
As evidence to this, Archimedes' Biosimilar Fill Rate™ was 94% in 2023 for drugs that had a biosimilar available throughout all of 2023.

ARCHIMEDES ANNOUNCES BIOSIMILARS FIRST™, AN INDUSTRY LEADING PROGRAM TO DRIVE BIOSIMILAR ADOPTION IN 2024

BRENTWOOD, Tenn., Jan. 11, 2024 /PRNewswire/ -- Archimedes, a recognized leader in specialty drug management solutions, announced BiosimilarsFirst^™, a program, which excludes Humira from formulary in favor of low cost, low WAC biosimilars. BiosimilarsFirst is projected to drive industry-leading adoption of biosimilars for autoimmune diseases, providing plan sponsor savings of 65% plus and more affordable treatment options for patients.

The FDA approved nine biosimilars for Humira in 2023, which includes both high WAC versions (priced ~5% lower than Humira) and low WAC versions (priced ~55%+ lower than Humira). Major PBMs are making the brand and high cost, high WAC biosimilars easily available to patients while limiting promotion of or restricting access to the lower cost biosimilars, a move that keeps plan and patient costs high and preserves the PBM's existing revenue streams. Archimedes' BiosimilarsFirst program stands in direct contrast to the PBM market's approach by preferring low cost biosimilars and excluding both brand and high cost biosimilars.

"The larger PBMs in the market derive higher profits on Humira and high WAC biosimilars through rebate keep and fulfillment at PBM-owned pharmacies. With these financial conflicts in place, we expect the market will see substantial utilization of Humira and high WAC biosimilars in 2024," said Dr. Brenda Motheral PhD, CEO and Co-Founder of Archimedes. "Our aligned business model gives Archimedes the freedom to exclude Humira, making our clients optimally positioned to capture greater savings than other plan sponsors while increasing patient affordability."

Archimedes has proven expertise in working with members and physicians to move to biosimilars for their Fortune 500 and smaller employer clients. As evidence to this, Archimedes' Biosimilar Fill Rate^™ was 94% in 2023 for drugs that had a biosimilar available throughout all of 2023. As part of their commitment to transparency, Archimedes will be publishing their Biosimilar Fill Rate^™ on their website and through social media throughout 2024, allowing the market to track the success of the BiosimilarsFirst program.

About Archimedes

Archimedes is an industry leader in specialty drug management solutions. Founded with the goal of transforming the PBM industry to promote sustainable prescription drug benefits through alignment, value and transparency, Archimedes achieves superior results by eliminating traditional PBM conflicts of interest including drug spread, rebate retention and pharmacy ownership and delivering the most rigorous clinical management at the lowest net cost.

For media inquiries: [email protected].

View original content to download multimedia:https://www.prnewswire.com/news-releases/archimedes-announces-biosimilars-first-an-industry-leading-program-to-drive-biosimilar-adoption-in-2024-302032806.html

SOURCE Archimedes